SCHEMBL5066567

SCHEMBL5066567

Nc1c(O)ccc2c1Oc1cc(O)ccc1C21OC(=O)c2ccccc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 8/20 0.74
MAPT P10636 5/20 0.74
MEN1 O00255 5/20 0.74
KMT2A Q03164 5/20 0.74
TDP1 Q9NUW8 4/20 0.74
HTT P42858 2/20 0.74
RECQL P46063 2/20 0.74
BLM P54132 2/20 0.74
PRMT1 Q99873 2/20 0.74
ACE2 Q9BYF1 2/20 0.74
HPGD P15428 2/20 0.74
CYP2C19 P33261 1/20 0.74
SMAD3 P84022 1/20 0.74
GNG2 P59768 1/20 0.60
GNB1 P62873 1/20 0.60
LMNA P02545 4/20 0.56
GPR55 Q9Y2T6 2/20 0.56
POLB P06746 2/20 0.56
ALOX12 P18054 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31326016 0.89 FTO (0.76) FTOMAPTMEN1KMT2ATDP1
SCHEMBL17201722 0.87 GNG2 (0.76) FTOMAPTMEN1KMT2ATDP1
SCHEMBL29756279 0.87 FTO (0.73) FTOMAPTMEN1KMT2ATDP1
SCHEMBL8417826 0.87 FTO (0.73) FTOMAPTMEN1KMT2ATDP1
SCHEMBL20907331 0.87 FTO (0.73) FTOMAPTMEN1KMT2ATDP1
SCHEMBL8607854 0.87 FTO (0.73) FTOMAPTMEN1KMT2ATDP1
SCHEMBL3652107 0.87 FTO (0.73) FTOMAPTMEN1KMT2ATDP1
SCHEMBL5359408 0.87 FTO (0.73) FTOMAPTMEN1KMT2ATDP1
SCHEMBL17025371 0.86 FTO (0.68) FTOMAPTMEN1KMT2ATDP1
SCHEMBL499201 0.86 FTO (0.68) FTOMAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889324-B1 Process for the determination of potassium ions NOVARTIS AG (CH) 2006-09-13 EP claimed
US-5099020-A Immunoassay with fluorescent compounds ABBOTT LABORATORIES (US) 1992-03-24 US claimed
WO-2022038359-A1 CROSS-LINKING METHOD AND APPLICATIONS IN BIOCONJUGATION UNIVERSITY OF DURHAM (GB) 2022-02-24 WO disclosed
US-20080152640-A1 Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer UNIVERSITATSKLINIKUM MUNSTER (DE) 2008-06-26 US disclosed
US-20070221884-A1 Liminescent Silicon Oxide Flakes CIBA SPECIALTY CHEMICALS CORP. 2007-09-27 US disclosed
EP-1468107-A4 METHODS AND REAGENTS FOR IMPROVED CELL-BASED ASSAYS BECKMAN COULTER INC (US) 2007-05-02 EP disclosed
EP-1769049-A2 LUMINESCENT SILICON OXIDE FLAKES Ciba Specialty Chemicals Holding Inc. (CH) 2007-04-04 EP disclosed
EP-0889324-B1 Process for the determination of potassium ions NOVARTIS AG (CH) 2006-09-13 EP disclosed
WO-2006008239-A2 LUMINESCENT SILICON OXIDE FLAKES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-01-26 WO disclosed
EP-1468107-A2 METHODS AND REAGENTS FOR IMPROVED CELL-BASED ASSAYS Beckman-Coulter, Inc. (US) 2004-10-20 EP disclosed
WO-2003034025-A2 METHODS AND REAGENTS FOR IMPROVED CELL-BASED ASSAYS BECKMAN-COULTER, INC. (US) 2003-04-24 WO disclosed
EP-1036763-B1 Process for the preparation of coloured and fluorescent polysilicic acid particles MICROMOD PARTIKELTECHNOLOGIE G (DE) 2001-12-05 EP disclosed
US-6245574-B1 ACTIVE LAYER CONTAINS A POLYMER IN WHICH IS DISPERSED AT LEAST ONE MODIFIED VALINOMYCIN, IN WHICH A RADICAL OF A FLUORESCENCE DYE WHICH EMITS IN LONG WAVES, PREFERABLY AN ACRIDINE OR FLUORESCEIN NOVARTIS AG (CH) 2001-06-12 US disclosed
EP-1036763-A1 Process for the preparation of coloured and fluorescent polysilicic acid particles micromod Partikeltechnologie GmbH (DE) 2000-09-20 EP disclosed
EP-0889324-A1 Sensors for the determination of potassium ions Novartis AG (CH) 1999-01-07 EP disclosed
US-5776720-A COMPOUND OR SALT FOR ASSAYING ACTIVITY OF AN ENZYME INSIDE A METABOLICALLY ACTIVE WHOLE CELL COULTER CORPORATION (US) 1998-07-07 US disclosed
EP-0832279-A1 AN ASSAY REAGENT AND A METHOD OF MAKING AND USING THE ASSAY REAGENT Coulter International Corp. (US) 1998-04-01 EP disclosed
WO-1996036729-A1 AN ASSAY REAGENT AND A METHOD OF MAKING AND USING THE ASSAY REAGENT COULTER INTERNATIONAL CORP. (US) 1996-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152640-A1 Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer ABCB1, ABCB11, SLC47A2 FTO 3724/4885MAPT 2282/4885MEN1 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.